Safety, Pharmacokinetics and Preliminary Efficacy of Asimadoline in Pruritus Associated With Atopic Dermatitis
Status:
Completed
Trial end date:
2017-06-01
Target enrollment:
Participant gender:
Summary
Kappa-opioid receptors mediate the sensation of itch in animals and humans. Asimadoline is an
orally active, selective kappa-opioid receptor agonist and has demonstrated efficacy in
several preclinical pruritus models. The purpose of this Phase 2 study is to evaluate the
safety, tolerability and clinical efficacy of asimadoline in patients with pruritus
associated with atopic dermatitis.